Updated Pneumococcal Vaccine Strategies Target Evolving Adult Risks

Pneumococcal vaccination guidelines for at-risk adults are updating to keep pace with evolving bacterial strains and new high-potency vaccines, according to the Journal of Microbiology, Immunology, and Infection.¹

“Pneumococcal infections, caused by Streptococcus pneumoniae (commonly known as pneumococcus or [S. pneumoniae]), remain a major public health concern. Pneumococcus commonly colonizes the human respiratory tract and spreads from person to person through direct contact with saliva or respiratory secretions,” wrote the authors of the study. “These infections vary in severity, ranging from non-invasive conditions such as sinusitis, otitis media, and non-bacteremic pneumonia to invasive pneumococcal diseases (IPD), which include bacteremia, bacteremic pneumonia, empyema, and meningitis.”

The landscape of adult immunization is undergoing a transformative shift as clinicians and pharmacists respond to the evolving threat of IPD. Leading this transition, 8 national academic societies in Taiwan recently collaborated to release comprehensive guidance for adult pneumococcal vaccination, emphasizing the need for strategies tailored to local epidemiology and individual risk factors.¹

This effort reflects a broader global urgency, as research indicates that the incidence of IPD nearly doubled between 2012 and 2024, underscoring the limitations of older vaccine formulations in the face of emerging nonvaccine serotypes.² For pharmacists, who serve as frontline educators and immunizers, staying current with these updates is essential for protecting vulnerable populations, according to U.S. Pharmacist.³

READ MORE: New Weekly System Can Track Severe Pneumococcal Infections

Pneumococcal infections, caused by the gram-positive bacterium S. pneumoniae, range from common conditions like sinusitis to life-threatening syndromes, including bacteremia and meningitis.^3,4 Although routine pediatric vaccination has successfully lowered the overall disease burden through herd immunity, the persistence of specific strains like serotype 19A and the rise of multidrug-resistant strains such as 15A and 23A continue to challenge public health.^1,2

In response to these dynamics, both Taiwanese and US authorities have expanded routine vaccination recommendations to include all adults 50 years and older—a significant change from the previous threshold of 65 years.^1,3,5 This expansion is particularly crucial for individuals with chronic medical conditions like diabetes, heart disease, or chronic obstructive pulmonary disease, as well as those with immunocompromising conditions such as HIV, multiple myeloma, or those undergoing organ transplants.^1,4

The introduction of higher-valency pneumococcal conjugate vaccines (PCVs), specifically PCV20 and PCV21, has simplified the clinical approach by offering robust protection often achievable in a single dose. In Taiwan, these vaccines are proposed as effective alternatives to complex sequential strategies that previously required multiple doses of different vaccine types spaced a year apart.^1,5

PCV21 is of particular interest because it targets 8 emerging strains not covered by previous vaccines, though its use is most appropriate in regions where older serotypes are already well-controlled. Pharmacists utilizing digital tools to navigate these complex recommendations—such as the CDC’s PneumoRecs VaxAdvisor app—must ensure they are accessing information through secure, verified platforms, occasionally managing technical requirements like browser security checks to maintain the integrity of patient guidance.^1,3,5

Pharmacists must also remain vigilant regarding local serotype variations; for example, though PCV21 offers broad coverage for emerging strains, it lacks the original serotypes found in earlier vaccines like PCV7, which may still circulate in certain regions or among international travelers. Furthermore, in the US, specific concerns have been raised about serotype 4, which has reemerged in certain western regions and among specific risk groups, potentially influencing the choice between different conjugate vaccines.^1,3

Pharmacists can further optimize patient outcomes by co-administering pneumococcal vaccines with seasonal influenza or COVID-19 shots, a practice that has been shown to be safe and effective in reducing the risk of severe coinfections during respiratory seasons.

By moving toward a shared decision-making model that considers an individual’s age, health status, and prior vaccination history, pharmacists can ensure that adult patients receive the most effective protection against the shifting landscape of pneumococcal disease.

“The recommendations in this guidance are based on current epidemiological data and available clinical evidence and are intended to give health care providers clear guidance for selecting an optimal vaccine strategy for protecting at-risk adults against pneumococcal disease,” concluded the authors of the study.¹ “Ongoing surveillance and periodic reassessment and updates of these recommendations are necessary to ensure that adult pneumococcal vaccination strategies remain optimal and provide the broadest and most effective protection for vulnerable populations.”

READ MORE: Pneumococcal Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Lin I-Fan, Lin KY, Su LY, et al. Recommendations and guidance for pneumococcal vaccination for adults in Taiwan. J Microbiol Immunol Infect. April 6, 2026. https://doi.org/10.1016/j.jmii.2026.04.001

2. Nowosielski B. Rise in IPD calls for development of more pneumococcal vaccines. Drug Topics. November 17, 2025. Accessed April 7, 2026. https://www.drugtopics.com/view/rise-in-ipd-calls-for-development-of-more-pneumococcal-vaccines

3. Calliste S, Herrod A, Sucher A, et al. Updated recommendations for pneumococcal vaccination. U.S. Pharmacist. May 14, 2025. Accessed April 7, 2026. https://www.uspharmacist.com/article/updated-recommendations-for-pneumococcal-vaccination-1

4. Clinical overview of pneumococcal disease. CDC. February 25, 2026. Accessed April 7, 2026. https://www.cdc.gov/pneumococcal/hcp/clinical-overview/index.html

5. Pneumococcal vaccine recommendations. CDC. February 25, 2026. Accessed April 7, 2026. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html